TC Biopharm Celebrates Successful Completion of $2.0 Million Public Offering: A Milestone for Medical Advancement
EDINBURGH, Scotland, Aug. 15, 2024 /PRNewswire/ — TC BioPharm (Holdings) PLC
TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the closing of its previously announced public offering of 2,000,000 shares of its American Depository Shares (“ADSs”)(or pre-funded warrants in lieu thereof), together with Series G warrants (“Series G Warrants”) to purchase up to 2,000,000 ADSs at a combined public offering price of $1 per ADS (or pre-funded warrant in lieu thereof) and associated Series G Warrant. The Series G Warrants have an exercise price of £0.78 per ADS, are exercisable upon issuance and will expire one year from the date of issuance.
TC BioPharm has reached a significant milestone in its journey towards revolutionizing medical treatment with the successful completion of their $2.0 million public offering. This achievement marks a pivotal moment not only for the company but also for the advancement of medical science and the potential impact it can have on patients worldwide.
With a focus on developing innovative allogeneic gamma-delta T cell therapies for cancer and other conditions, TC BioPharm is at the forefront of cutting-edge biotechnology. The completion of this public offering signifies a vote of confidence from investors in the company’s vision and potential to make a meaningful difference in the field of medicine.
By raising these funds, TC BioPharm will be able to accelerate its research and development efforts, bringing new treatment options to those in need and pushing the boundaries of what is possible in the fight against disease. The Series G Warrants associated with the public offering also provide additional opportunities for future growth and expansion.
As we celebrate this milestone with TC BioPharm, we are reminded of the power of scientific innovation and the dedicated individuals working tirelessly to transform healthcare for the better. The impact of this successful public offering extends beyond financial gain, paving the way for advancements in medical technology that have the potential to save lives and improve outcomes for countless individuals.
How This Will Affect Me
As a potential beneficiary of medical advancements, the successful completion of TC BioPharm’s public offering could mean access to cutting-edge treatments and therapies for various conditions, including cancer. This milestone signals progress towards a future where innovative medical solutions offer hope and improved outcomes for patients like you.
How This Will Affect the World
The implications of TC BioPharm’s successful public offering extend globally, with the potential to impact healthcare systems around the world. By advancing the field of biotechnology and developing novel treatment options, TC BioPharm is contributing to a brighter future where diseases can be treated more effectively, ultimately benefiting individuals and communities worldwide.
Conclusion
In conclusion, TC BioPharm’s achievement of completing a $2.0 million public offering represents a significant step forward in the realm of medical advancement. With a focus on developing cutting-edge gamma-delta T cell therapies, TC BioPharm is poised to make a lasting impact on the field of biotechnology and healthcare. This milestone not only showcases the company’s potential for growth and innovation but also underscores the importance of continued investment in scientific research for the betterment of society as a whole.
